A Form 4 filed on September 16, 2026, with the SEC discloses that Stephen Hoge, President of Moderna, Inc. (NASDAQ:MRNA), exercised stock options and sold common stock on September 14 and September 15, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercises: Hoge exercised stock options to acquire 76,453 shares on September 14, 2026, and 76,452 shares on September 15, 2026, both at an exercise price of $12.21 per share.
  • Shares sold on September 14: 40,294 shares of common stock were disposed of at a weighted average price of $144.13, with individual transactions ranging from $143.99 to $144.66.
  • Shares sold on September 15: 40,281 shares of common stock were disposed of at a weighted average price of $146.07, with individual transactions ranging from $145.97 to $146.27.
  • Direct beneficial ownership after transactions: Hoge directly held 1,562,029 shares of common stock following the September 15 transactions.
  • Indirect holdings: Hoge also holds 4,116 shares indirectly through Valhalla, LLC and 151,933 shares indirectly through a trust for the benefit of his spouse and children.
  • Trading plan: All reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.

Moderna President Exercises Options and Sells Stock Over Two-Day Period

According to the filing, Stephen Hoge, serving as President of Moderna, Inc., executed a series of transactions on September 14 and September 15, 2026. On each day, Hoge exercised fully vested stock options - 76,453 shares on the first day and 76,452 shares on the second - converting them from derivative securities into common stock at an exercise price of $12.21 per share. The options carry an expiration date of February 23, 2027. Following both exercises, Hoge's remaining stock option position stood at 305,810 shares, the filing reported.

Concurrent with each option exercise, the filing discloses that Hoge sold a portion of the acquired shares. On September 14, he sold 40,294 shares at a weighted average price of $144.13. On September 15, he sold 40,281 shares at a weighted average price of $146.07. Both sale prices reflect weighted averages across multiple transactions, and the filing notes that full details on shares sold at each separate price are available to SEC staff upon request.

The filing further discloses that all transactions were made pursuant to a Rule 10b5-1 trading plan that Hoge adopted on June 15, 2026. In addition to his direct holdings of 1,562,029 shares after the reported transactions, Hoge holds 4,116 shares indirectly through Valhalla, LLC and 151,933 shares indirectly through a trust. According to the filing, the trust shares "are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee," and Hoge "disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any."

What Was Disclosed

Moderna President Stephen Hoge disclosed the exercise of stock options totaling 152,905 shares and the sale of 80,575 shares of common stock across September 14-15, 2026, all conducted under a Rule 10b5-1 plan adopted June 15, 2026.